Biomechanics of the progression of colorectal carcinomas Giulia Fornabaio, Synthetic morphogenesis group According to the World Health Organization, cancer is one of the main causes of death worldwide, with colorectal carcinoma (CRC) being the second-leading cause of tumour related-death. The high rate of mortality of CRCs is principally attributed to the metastasis of neoplastic cells ... Read more
IBEC Seminar
Calendario de Eventos
L
Lun
|
M
Mar
|
X
Mié
|
J
Jue
|
V
Vie
|
S
Sáb
|
D
Dom
|
---|---|---|---|---|---|---|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
1 evento,
–
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
0 eventos,
|
3 eventos,
–
Regenerative Neuroimmunology - new generation molecular approaches to restore maladaptive inflammatory responses in the persistently inflamed CNS Stefano Pulchino, University of Cambridge There are currently no approved therapies to slow down the accumulation of neurological disability that occurs independently of relapses in multiple sclerosis (MS). International agencies are engaging to expedite the development of novel ... Read more
–
Regenerative Neuroimmunology - new generation molecular approaches to restore maladaptive inflammatory responses in the persistently inflamed CNS Stefano Pulchino, University of Cambridge There are currently no approved therapies to slow down the accumulation of neurological disability that occurs independently of relapses in multiple sclerosis (MS). International agencies are engaging to expedite the development of novel ... Read more
–
Regenerative Neuroimmunology - new generation molecular approaches to restore maladaptive inflammatory responses in the persistently inflamed CNS Stefano Pulchino, University of Cambridge There are currently no approved therapies to slow down the accumulation of neurological disability that occurs independently of relapses in multiple sclerosis (MS). International agencies are engaging to expedite the development of novel ... Read more |
0 eventos,
|
0 eventos,
|